NeuBase Therapeutics Inc. (NBSE) closed Friday’s after-hours trading at $5.87, up 9.72%. NeuBase’s stock price finished last trading session up 5.31% at $5.35. A range of $4.96-$5.39 was observed for NBSE stock.
NBSE stock traded 2.29 million shares, which was above its daily average of 0.34 million shares over 100 days. The NBSE’s shares have advanced by 15.55 percent in the last five days, while they have gained 2.6 percent in the last month. NBSE’s stock gained after the company offered an oncology program that demonstrated functional rescue.
What was the NBSE program?
In its mission to accelerate the genetic revolution, NeuBase is developing a new class of precision genetic medicines. These medicines will be able to change or increase gene function depending on the genetic defect. Targeted PATrOL therapies develop by NBSE combine genetic therapies with small molecules to effectively treat disorders at the DNA/RNA level and are highly targeted, therefore combining the advantages of small molecules with the broad organ distribution capabilities of genetic therapies. NBSE first focused on redefining medicine for patients suffering from debilitating neurological, neuromuscular, or oncologic conditions with what it calls specific genes that silence disease-causing mutations.
Earlier this month, NeuBase announced new data and program updates regarding its genetic medicine development pipeline based on PATrOL technology.
- NBSE was able to find ways to utilize the PATrOL platform to identify drug candidates that could interfere with DNA transcription, RNA translation, and mutant protein production, including dislodging bound proteins to aid mis-splicing.
- In addition, NBSE has made significant progress since its last report, showing functional recovery after subcutaneous dosing in patients suffering from myotonic dystrophy type 1.
- The NBSE data demonstrated that compounds could cross the blood-brain barrier in vivo by allele-selective mutant protein knock-down in Huntington’s disease.
- In 2022, NBSE will have its DM1 program in the clinic as a result of the tremendous momentum it is building across its expanding development pipeline.
- Also, the NBSE will continue to explore diseases where the PATrOL platform can provide significant therapeutic benefits.
How NBSE will excel through its platform?
PATrOL, NeuBase (NBSE)’s platform technology, enables it to generate precision genetic medicines with unrivaled flexibility aimed at distinct genetic disorders based on data from several programs in its pipeline. As demonstrated by the successful application of NBSE’s platform to three disease indications with different mechanisms of disease, its platform can regulate gene function in vivo at the RNA and DNA levels with high precision.
